Universally optimal crossover designs for the estimation of mixed-carryover effects with an application to biosimilar development
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Discussion Paper / SFB823 ; 3/2018
- Keyword
-
Versuchsplanung
Carry over Effect
Arzneimittel
- Event
-
Veröffentlichung
- (where)
-
Dortmund
- (who)
-
Universitätsbibliothek Dortmund
- (when)
-
2018
- Creator
- Handle
-
2003/36785
- URN
-
urn:nbn:de:101:1-2018060103593373005425
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mielke, Johanna
- Kunert, Joachim
- Universitätsbibliothek Dortmund
Time of origin
- 2018
Other Objects (12)
MSE-optimale crossover designs
Optimal crossover designs in a model with self and mixed carryover effects
Optimal crossover designs in a model with self and mixed carryover effects
On MSE-optimal crossover designs
On MSE-Optimal Circular Crossover Designs
Optimal crossover designs in a model with self and mixed carryover effects with correlated errors
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Introduction to optimal estimation
MYL-1402O: A Bevacizumab Biosimilar
MSE-optimale crossover designs
Optimal crossover designs in a model with self and mixed carryover effects
Optimal crossover designs in a model with self and mixed carryover effects
On MSE-optimal crossover designs
On MSE-Optimal Circular Crossover Designs
Optimal crossover designs in a model with self and mixed carryover effects with correlated errors
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Introduction to optimal estimation
MYL-1402O: A Bevacizumab Biosimilar
MSE-optimale crossover designs
Optimal crossover designs in a model with self and mixed carryover effects
Optimal crossover designs in a model with self and mixed carryover effects
On MSE-optimal crossover designs
On MSE-Optimal Circular Crossover Designs
Optimal crossover designs in a model with self and mixed carryover effects with correlated errors
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Introduction to optimal estimation